All the doctors who gave
evidence at trial agreed that the Plaintiff «suffered a slight tear to the cartilage of her left hip (a labral tear) and a disc bulge in the lumbar spine, and that these two conditions contribute to her ongoing pain...»
Not exact matches
These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical
trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not
agree with our regulatory approval strategies or components of our filings for our products, including our clinical
trial designs, conduct and methodologies and, for ALKS 5461,
evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or
at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical
trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website
at www.sec.gov.
At the end of the day, all
trial counsel
agreed that the party offering the
evidence was actually in a very bad position.
I suggest it is probable that the dissenting judge
agreed on this point
at least because the dissent was «merely» on the question of whether there was sufficient admissible
evidence to support the
trial judge's decision.
Mr. Justice Punnett
agreed and provided the following reasons explaining the limitation of discovery
evidence at trial:
If the court
agrees to admit the prosecutors»
evidence at trial, the lawyer will make all the arrangements to present a fair plea and sentencing agreements.
Failure to
agree results in the court deciding custody after taking testimony and
evidence from both parents
at trial.
Abrams Realty Corp. v. Elo (279 A.D. 2d 261)-
trial evidence establishes that broker was the procuring cause of sale of property; brokerage agreement was not unenforceable for its failure to specify rate
at which broker's commission would be computed since it was clear that broker did not
agree to work without compensation and that the parties understood that the broker would be compensated
at the prevailing, normal and accepted rates;
trial court properly rejected attempt to evade obligation to pay broker's commission by endeavoring to characterize the transaction as merely the assignment of a successful bid